Long-Term Adherence to Evidence-Based Secondary Prevention Therapies in Coronary Artery Disease
L. Kristin Newby(Duke University), Robert M. Califf(Duke University), Anita Y. Chen(University of Rochester Medicine), Nancy M. Allen LaPointe(Duke Medical Center), Lawrence H. Muhlbaier(Clinical Research Institute), Judith M. Kramer(United States Food and Drug Administration), Elizabeth R. DeLong(Duke University), Bradley G. Hammill(Duke University)
Cited by 507
Related Papers
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
|New England Journal of Medicine|2003|2.5k
Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction
|New England Journal of Medicine|2004|1.9k
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
|The Lancet|2018|1.8k
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease
|Journal of the American College of Cardiology|2016|1.6k